Corporate Office & Central Laboratory : Survey No 9/1, Near Tulsiyana Industrial Park, Gram Kumerdi, Indore (M.P.) - 453555 Tel: +91 731 4243850 - 88 Fax: +91 731 2490593

Email: compilance_officer@choksilab.com Website: www.choksilab.in CIN: L85195MP1993PLC007471



Date: 13th August, 2025

To,
The Corporate Relationship Department
BSE Limited
Phiroze Jeejeebhoy Tower
Dalal Street, Fort
Mumbai-Maharashtra 400001

<u>Subject: Outcome of Board Meeting held on 13th August, 2025 pursuant to regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015</u>

Ref: Scrip Code: 526546, ISIN: INE493D01013.

Dear Sir/Madam,

- 1. Considered and approved **Unaudited Standalone Financial Results** for the Quarter ended 30th June, 2025 along with the Limited review report;
- 2. Decided the date for closure of Register of Members and share transfer Books of the Company from Wednesday 10th September, 2025 to Tuesday 16th September, 2025 (both days inclusive) for the purpose of 32nd Annual General Meeting;
- 3. Finalized the **cut off date and remote e-voting period** for the ensuing AGM;
- Considered, Approved and Adopted the Board's Report and all the annexure including Corporate Governance Report and Management Discussion & Analysis Report (MDAR) for the Financial Year ended 31st March 2025;
- 5. Approved **Notice of 32nd Annual General Meeting** and decided the date of 32nd Annual General Meeting to be held on Tuesday, the 16th day of September, 2025. through Video Conferencing ("VC") or Other Audio-Visual Means ("OAVM");
- Considered and approved the Re-appointment of Mr. Vyangesh Choksi (DIN: 00154926) as Whole Time Director of the company subject to approval from shareholders in the ensuing AGM;
- Approved the appointment of M/s Surabhi Agrawal & Associates, as Secretarial Auditor for conducting the Secretarial Audit of the company for period of five consecutive years commencing from FY 2025-2026 till FY 2029-2030;
- 8. Approved the re-appointment of **M/s Tanmay V. Rajurkar & Co. as Internal Auditor** for conducting the Internal Audit of the company for the F.Y. 2025-26;

Corporate Office & Central Laboratory: Survey No 9/1, Near Tulsiyana Industrial Park, Gram

Kumerdi, Indore (M.P.) - 453555 Tel: +91 731 4243850 - 88 Fax: +91 731 2490593

Email: compliance_officer@choksilab.com

CIN: L85195MP1993PLC007471

Website: www.choksilab.in



9. Appointment of CS Surabhi Agrawal, Practicing Company Secretary as Scrutinizer for conducting the e-voting process in the ensuing AGM of the Company:

10. Other routine businesses with the permission of chair.

Further, Continuous Disclosure as required pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Circular No. SEBVHO/CFD/CFD-PoD-1/P/CIR/2023/123 dated 13th July 2023 and SEBI Circular No. SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31, 2024 with reference to appointment of Secretarial Auditor, Internal Auditor and Mr. Vyangesh Choksi as Whole Time Director of the Company are being submitted separately in pdf and xbrl form. Further, copy of Un-Audited Standalone Financial Results shall also be submitted in XBRL mode within 24 hours from the conclusion of Board Meeting.

The meeting of Board of Directors commenced at **02:30 P.M**. and concluded at **03:10P.M**.

You are requested to please take on record the same.

Thanking You,

Yours faithfully,

FOR CHOKSI LABORATORIES LIMITED

PRAKHAR DUBEY COMPANY SECRETARY & COMPLIANCE OFFICER

Encl.: Un-audited Financial Results along with limited review report for quarter ended on 30th June, *2025.*



PRATEEK JAIN & CO.

CHARTERED ACCOUNTANTS
405, SHALIMAR CORPORATE CENTRE, 8-B, SOUTH TUKOGANJ, INDORE (M.P.) 452001
PH. 9827013187, 731-3590283

E-MAIL: teamca@rediffmail.com

Independent Auditor's Review Report on the unaudited Quarterly Standalone Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations , 2015, as amended

To,
The Board of Directors
Choksi Laboratories Limited
Indore (M.P.) - 452001

We have reviewed the accompanying statement of unaudited financial results of **CHOKSI LABORATORIES LIMITED** ("the Company") for the quarter ended **June 30, 2025** ("the statement") attached herewith, being submitted by the Company pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended ("the listing regulations").

This statement, which is the responsibility of the Company's management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 (Ind AS 34) "Interim Financial Reporting" prescribed under section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 (as amended) and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE 2410) "Review of Interim Financial Information Performed by Independent auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

INDIA

PRATEEK JAIN & CO.

CHARTERED ACCOUNTANTS
405, SHALIMAR CORPORATE CENTRE, 8-B, SOUTH TUKOGANJ, INDORE (M.P.) 452001
PH. 9827013187, 731-3590283

E-MAIL: teamca@rediffmail.com

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in all material respect in accordance with the applicable recognition and measurement principles laid down in the aforesaid Indian Accounting Standard (Ind AS) prescribed under section 133 of the Companies Act, 2013 as amended, read with relevant rules issued there under and other recognized accounting practices generally accepted in India, has not disclosed the information required to be disclosed in terms of Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

FOR PRATEEK JAIN AND CO. CHARTERED ACCOUNTANTS FRN-009494C

> PRATEIK JAIIN PROPRIETOR M.NO.079214

Date: 13th August,2025

Place: Indore

UDIN: 25079214BMOCCV5308

Corporate Office & Central Laboratory :

Survey No. 9/1., Balaji Tulsiyana Industrial Park,

Kumedi, Off. M.R. 10 Toll Naka, Indore – 452010, M.P. (India)

Tel. +91 731 3501112 (60 Lines) Email: bd@choksilab.com Website: www.choksilab.com



CHOKSI LABORATORIES LIMITED

I II III IV	PARTICULARS Revenue from Operations Other Operating Revenue	3 Month ended 30.06.2025 (Unaudited)	Quarter ended	Corresponding	(Rs. In Lacs Year ended Year to Date
I II III	Revenue from Operations	30.06.2025	Preceding 3	Corresponding 3 months	Year ended Year to Date
I II III	Revenue from Operations	30.06.2025	Preceding 3	Corresponding 3 months	Year to Date
I II III	Revenue from Operations	30.06.2025		Corresponding 3 months	
II III	Revenue from Operations		Mondi chaca	3 months	
II III	Revenue from Operations Other Operating Revenue			ended in the	figures for the
II III	Revenue from Operations Other Operating Revenue			previous year	current period
II III	Revenue from Operations Other Operating Revenue	(Unaudited)	31.03.2025	30.06.2024	31.03.2025
II III	Other Operating Revenue	(onadarcca)	(Audited)	(Unaudited)	(Audited)
III	Tother Operating Revenue	1124.19	1139.95	1073.64	4178.23
	Total Davis Co.	0.33	4.43	0.54	6.71
	Total Revenue from Operations (Net) (I+II) Expenses	1124.52	1144.38	1074.18	4184.94
					.101.71
	(a) Cost of materials consumed	84.50	80.09	87.63	309.82
	(b) Employee benefits expenses (c) Finance Cost	459.24	451.86	393.86	1697.66
	(d) Dangagistian and	60.10	58.15	71.89	264.93
	(d) Depreciation and amortisation expenses	167.59	170.45	150.38	649.88
	(e) Laboratory Maintainance Expenses	112.80	84.82	115.76	408.95
	(f) Power & Fuel Charges	29.55	22.23	26.83	98.77
	(g) Other expenses Total Expenses	148.00	150.84	166.33	539.60
		1,061.78	1,018.44	1,012.68	3,969.61
V	Profit / (Loss) from operations before				0,707.01
VI	exceptional items and tax (III-IV) Exceptional items	62.74	125.94	61.50	215.33
00 00		-	-	-	210.00
VIII	Profit / (Loss) before tax (V-VI)	62.74	125.94	61.50	215.33
	Tax Expenses				213.33
	(a) Current Tax	9.93	12.63	10.51	33.38
-	(b) Income Tax Earlier Year	-	-		55.50
-	(c) Mat Credit Utilization/ (Entitlement)	1.88	46.13	(10.51)	39.50
	(d) Deferred Tax	12.43	(24.95)	19.43	(9.88)
1	Net Profit / (Loss) for the period from				(5.00)
IX	continuing operations (VII-VIII)	38.50	92.13	42.07	152.33
	Other Comprehensive Income				102.00
X	(a) (i) Items that will not be reclassified to profit				
-	& loss	(1.31)	(30.06)	0.61	(5.23)
,	(ii) Income tax relating to items that will not			0.01	(3.23)
	be reclassified to profit & loss	0.34	7.82	(0.16)	1.36
	(b) (i) Items that will be re-classified to profit &			(3.23)	1.50
		2.57	(3.46)	7.35	(15.51)
	(ii) Income tax relating to items that will be				(13.51)
7	reclassified to profit & loss	(0.67)	0.90	(1.91)	4.03
XI D	Total Comprehensive Income (IX+X)	39.43	67.33	47.96	136.98
	Details of equity share capital				150.56
(11)	a) Paid-up equity share capital	696.52	696.52	696.52	696.52
-1	b) Face value of equity share capital (in Rs)	10.00	10.00	10.00	10.00
TII C	arnings per equity share (for continuing operations)			20.00	10.00
	a) Basic	0.55	1.32	0.60	2.19
	b) Diluted	0.55	1.32	0.60	2.19
VI C	arnings per equity share for (Dis-continuing operations)			0.50	2.19
	a) Basic	-	-		
_	b) Diluted			-	———
V (a	arnings per equity share (for Dis-continued and continuing operation)	ations)			
v (a	a) Basic	0.55	1.32	0.60	2 10
(1	o) Diluted	0.55	1.32	0.60	2.19

Cont...



Corporate Office & Central Laboratory:

Survey No. 9/1., Balaji Tulsiyana Industrial Park,

Kumedi, Off. M.R. 10 Toll Naka, Indore – 452010, M.P. (India)

Tel. +91 731 3501112 (60 Lines) Email: bd@choksilab.com Website: www.choksilab.com



aOR

Page -2

Notes to the results:

- 1 The above financial results have been prepared as per the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) as amended, prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and other accounting principles generally accepted in India.
- 2 The above Financial Results for the quarter ended on 30th June 2025 have been reviewed by the Audit Committee and approved & taken on record by the Board at their Board meeting held on Wednesday, 13th August 2025.
- 3 The results for the quarter ended 30th June 2025 were subjected to "Limited Review" by the auditors and their report contains no qualification.
- 4 The figures for the quarter ended March 31, 2025 are balancing figures between audited figures in respect of full financial year ended March 31, 2025 and the unaudited published figures upto December 31, 2024 being the end of third quarter of the financial year which were subjected to limited review.
- 5 Depreciation on fixed assets is provided on straight line method as per the estimated remaining useful life of assets.
- 6 The Company has identified "Analysis and Testing" as the single operating segment for the continued operations in the financial statements as per Ind AS 108 "Operating Segments.
- 7 Earnings per share amount is shown in Rupees.

Date: 13th August 2025

Place: Indore

8 For any queries e_mail at compliance_officer@choksilab.com

For and on behalf of the Board of Directors of CHOKSI LABORATORIES LIMITED

Managing Director

DIN 00155078